Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Alpine Immune Sciences Inc ALPN

Healthcare Biotechnology
Alpine Immune Sciences, Inc. is a clinical-stage biopharmaceutical company, which is engaged in discovering and developing protein-based immunotherapies to treat autoimmune and inflammatory diseases. The Company’s approach includes a proprietary scientific platform that converts native immune system proteins into differentiated, multi-targeted therapeutics. Its ALPN-303 (povetacicept) is a dual... see more

Recent & Breaking News (NDAQ:ALPN)

Alpine Immune Sciences Reports First Quarter 2024 Financial Results

Business Wire 8 days ago

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CRC, HRT, ALPN, MCBC

PR Newswire April 29, 2024

ALPINE IMMUNE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Alpine Immune Sciences, Inc. - ALPN

Business Wire April 26, 2024

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AIRC, ALPN, WIRE

PR Newswire April 23, 2024

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ALPN, LABP, SWAV, FUSN

Accesswire April 22, 2024

INVESTIGATION: The M&A Class Action Firm Announces an Investigation of Alpine Immune Sciences, Inc. - ALPN

PR Newswire April 17, 2024

ALPINE IMMUNE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Alpine Immune Sciences, Inc. - ALPN

Business Wire April 12, 2024

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Alpine Immune Sciences, Inc. Buyout

Newsfile April 12, 2024

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ALPN, JBT, ELYM, HRT

Accesswire April 11, 2024

Kuehn Law Encourages ALPN, JBT, ELYM, and HRT Investors to Contact Law Firm

PR Newswire April 11, 2024

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ALPN, ELYM, MODN

PR Newswire April 11, 2024

Shareholder Alert: Ademi LLP investigates whether Alpine Immune Sciences, Inc. has obtained a Fair Price in its transaction with Vertex

PR Newswire April 10, 2024

ALPN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Alpine Immune Sciences, Inc. Is Fair to Shareholders

Business Wire April 10, 2024

Alpine Immune Sciences Shares Updated Clinical Data from Povetacicept in IgA Nephropathy

Business Wire April 10, 2024

Vertex Enters Into Agreement to Acquire Alpine Immune Sciences

Business Wire April 10, 2024

Alpine Immune Sciences to Present Updated Clinical Data for Povetacicept in IgA Nephropathy at the World Congress of Nephrology 2024

Business Wire April 1, 2024

Alpine Immune Sciences Presents New Translational Data on Povetacicept at the European Lupus Meeting 2024

Business Wire March 21, 2024

Alpine Immune Sciences to Participate in Upcoming H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference

Business Wire March 20, 2024

Alpine Immune Sciences Provides Corporate Update and Full Year 2023 Financial Results

Business Wire March 18, 2024

Alpine Immune Sciences to Report Fourth Quarter and Full Year 2023 Financial Results

Business Wire March 7, 2024